Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 12 de 12
Filtrar
2.
Pediatr Hematol Oncol ; 40(7): 607-616, 2023.
Artigo em Inglês | MEDLINE | ID: mdl-36420998

RESUMO

Strokes affect up to 10% of children with sickle-cell disease (SCD). The most commonly used strategy to prevent a first-time stroke or its recurrence is to perform periodic red blood cell transfusions. This article aims to evaluate the quality of life (QoL) of children and adolescents with SCD undergoing a chronic transfusion regimen (CTR) for stroke prophylaxis, according to their caregivers' perception. A cross-sectional study was conducted using a sociodemographic interview with an application of a validated instrument (Pediatric Quality of Life Inventory) involving 16 caregivers of patients with SCD aged <18 years undergoing CTR in a reference center. The data were processed using STATA version 13.0. The caregivers were predominantly the mothers of the minors that were part of the study cohort (87.5%), an income of <2 minimum wages (81.2% of cases) and >8 years of schooling (56.2%). The patients had a mean age of 10.4 years, 68.8% were male, 75% were mixed-race and came from small towns and rural areas (68.8%). The overall mean QoL was 45.8 (95% confidence interval [CI] 42.5-49.2). Female patients and those aged <12 years had lower levels of overall QoL. The emotional dimension of the children was the least compromised as per the caregivers' perception. The mean QoL of children with SCD on a CTR is lower than the estimated global mean QoL reported in the literature. It is possible that the occurrence of a stroke enhances the caregivers' negative perceptions about the QoL of patients with SCD.


Assuntos
Anemia Falciforme , Acidente Vascular Cerebral , Criança , Adolescente , Humanos , Masculino , Feminino , Qualidade de Vida/psicologia , Cuidadores/psicologia , Estudos Transversais , Anemia Falciforme/terapia , Acidente Vascular Cerebral/prevenção & controle
3.
Rev Bras Med Trab ; 21(3): e20221226, 2023.
Artigo em Inglês | MEDLINE | ID: mdl-38313786

RESUMO

The relationships between work and health/illness are the main task of the occupational physician, with the occupational medical examination being used to address these relationships, together with a workplace study and epidemiological analyses. This study had as a guiding clinical question: Is telemedicine occupational examination (telediagnosis) accurate compared with in-person occupational examination? The studies were selected by four independent reviewers, meeting the eligibility criteria. The searches resulted in 12,654, 29, 3, and 0 articles retrieved from MEDLINE, EMBASE, and Google Scholar databases and hand search, respectively. Of this total, 284 studies were selected by title and abstract screening, none of which met the previously established eligibility criteria for study inclusion (references excluded). There is currently no evidence comparing regular or standard (in-person) occupational examination vs telemedicine occupational examination. Therefore, there is no supporting evidence to recommend the use of occupational telediagnosis (occupational examination).


As relações entre trabalho e saúde/doença são a principal tarefa do médico do trabalho, sendo o exame ocupacional utilizado para abordar essas relações, juntamente com o estudo do local de trabalho e análises epidemiológicas. Este estudo teve como questão clínica norteadora: o exame ocupacional por telemedicina (telediagnóstico) é acurado quando comparado ao exame ocupacional presencial? Os trabalhos foram selecionados por quatro revisores independentes, atendendo aos critérios de elegibilidade. Foram recuperados, nas bases consultadas MEDLINE, EMBASE, Google Scholar e manual, respectivamente, 12.654, 29, 3 e 0 artigos. Desse montante, foi selecionado pelo título e resumo um total de 284 estudos (referências excluídas), dos quais não foi possível selecionar nenhum que atendesse aos critérios de elegibilidade previamente estabelecidos. No momento, não há evidência comparando o exame ocupacional regular ou padrão (presencial) e o mesmo exame por meio de telemedicina. Portanto, não há como recomendar o uso de telediagnóstico ocupacional (exame ocupacional).

6.
Rev Bras Med Trab ; 18(4): 369-370, 2021 Mar 03.
Artigo em Inglês | MEDLINE | ID: mdl-33688317
7.
World J Gastroenterol ; 27(2): 208-223, 2021 Jan 14.
Artigo em Inglês | MEDLINE | ID: mdl-33510560

RESUMO

BACKGROUND: Understanding the treatment landscape of inflammatory bowel diseases (IBD) is essential for improving disease management and patient outcomes. Brazil is the largest Latin American country, and it presents socioeconomic and health care differences across its geographical regions. This country has the highest increase in IBD incidence and prevalence in Latin America, but information about the clinical and treatment characteristics of IBD is scarce. AIM: To describe the sociodemographic, clinical, and treatment characteristics of IBD outpatients in Brazil overall and in the Southeast, South and Northeast/Midwest regions. METHODS: Multicenter, cross-sectional study with a 3-year retrospective chart review component. Patients with moderate-to-severe Crohn's disease (CD) or ulcerative colitis (UC) were consecutively enrolled between October 2016 and February 2017. Active CD at enrollment was defined as a Harvey Bradshaw Index ≥ 8 or a CD Activity Index ≥ 220 or a calprotectin level > 200 µg/g or an active result based on colonoscopy suggestive of inadequate control during the previous year; active UC was defined as a partial Mayo score ≥ 5. Descriptive statistics were used to analyze all variables. RESULTS: In a total of 407 included patients, CD was more frequent than UC, both overall (264 CD/143 UC patients) and by region (CD:UC ratios of 2.1 in the Southeast, 1.6 in the South and 1.2 in the Northeast/Midwest). The majority of patients were female (54.2% of CD; 56.6% of UC), and the mean ages were 45.9 ± 13.8 years (CD) and 42.9 ± 13.0 years (UC). The median disease duration was 10.0 (range: 0.5-45) years for both IBD types. At enrollment, 44.7% [95% confidence interval (CI): 38.7-50.7] of CD patients and 25.2% (95%CI: 18.1-32.3) of UC patients presented with active disease. More than 95% of IBD patients were receiving treatment at enrollment; CD patients were commonly treated with biologics (71.6%) and immunosuppressors (67.4%), and UC patients were commonly treated with mesalazine [5-Aminosalicylic acid (5-ASA)] derivates (69.9%) and immunosuppressors (44.1%). More than 50% of the CD patients had ileocolonic disease, and 41.7% presented with stricturing disease. One-quarter of CD patients had undergone CD-related surgery in the past 3 years, and this proportion was lower in the Northeast/Midwest region (2.9%). CONCLUSION: In Brazil, there are regional variations in IBD management. CD outweighs UC in both frequency and disease activity. However, one-quarter of UC patients have active disease, and most are receiving 5-ASA treatment.


Assuntos
Colite Ulcerativa , Doenças Inflamatórias Intestinais , Adulto , Brasil/epidemiologia , Colite Ulcerativa/diagnóstico , Colite Ulcerativa/tratamento farmacológico , Colite Ulcerativa/epidemiologia , Estudos Transversais , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos
8.
Rev. patol. trop ; 46(4): 287-305, dez. 2017. tab, graf
Artigo em Inglês | LILACS | ID: biblio-913716

RESUMO

Aim: to conduct a systematic literature review on dengue costs in Latin America, comparing study methodologies, disease costs and the economic impact of dengue in different countries. Methods: the literature search was carried out in the following electronic databases: MEDLINE/ PubMed, EMBASE and LILACS, for the period between 2004 and 2014. To make comparisons possible, the costs identified in the selected studies were converted to local currency values, adjusted to the consumer price index (2014) and converted to purchasing power parity (PPP). Results: 728 publications were identified in databases and 13 papers were selected for analysis. Nine of the thirteen studies were conducted from a societal perspective and three from a health system perspective. In most studies, indirect costs accounted for the largest percentage of total outpatient costs. In contrast, for hospitalized patients, direct medical costs showed the highest percentages. The economic impact of dengue was estimated at I$ 3.2 billion per year, ranging from I$ 1.4 to I$ 5.9 billion, when including the six sub-regions of the Americas. Conclusion: dengue represents a high cost for Latin American society and health system. Studies varied in terms of cost methodology (cost items included, such as direct medical and non-medical and indirect costs, and cost analysis) and the different epidemiological periods in which research was carried out (endemic and/or epidemic).


Assuntos
Dengue , Economia e Organizações de Saúde , Revisão , Custos e Análise de Custo , América Latina
9.
PLoS Negl Trop Dis ; 9(9): e0004042, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-26402905

RESUMO

BACKGROUND: Dengue is an increasing public health concern in Brazil. There is a need for an updated evaluation of the economic impact of dengue within the country. We undertook this multicenter study to evaluate the economic burden of dengue in Brazil. METHODS: We estimated the economic burden of dengue in Brazil for the years 2009 to 2013 and for the epidemic season of August 2012- September 2013. We conducted a multicenter cohort study across four endemic regions: Midwest, Goiania; Southeast, Belo Horizonte and Rio de Janeiro; Northeast: Teresina and Recife; and the North, Belem. Ambulatory or hospitalized cases with suspected or laboratory-confirmed dengue treated in both the private and public sectors were recruited. Interviews were scheduled for the convalescent period to ascertain characteristics of the dengue episode, date of first symptoms/signs and recovery, use of medical services, work/school absence, household spending (out-of-pocket expense) and income lost using a questionnaire developed for a previous cost study. We also extracted data from the patients' medical records for hospitalized cases. Overall costs per case and cumulative costs were calculated from the public payer and societal perspectives. National cost estimations took into account cases reported in the official notification system (SINAN) with adjustment for underreporting of cases. We applied a probabilistic sensitivity analysis using Monte Carlo simulations with 90% certainty levels (CL). RESULTS: We screened 2,223 cases, of which 2,035 (91.5%) symptomatic dengue cases were included in our study. The estimated cost for dengue for the epidemic season (2012-2013) in the societal perspective was US$ 468 million (90% CL: 349-590) or US$ 1,212 million (90% CL: 904-1,526) after adjusting for under-reporting. Considering the time series of dengue (2009-2013) the estimated cost of dengue varied from US$ 371 million (2009) to US$ 1,228 million (2013). CONCLUSIONS: The economic burden associated with dengue in Brazil is substantial with large variations in reported cases and consequently costs reflecting the dynamic of dengue transmission.


Assuntos
Efeitos Psicossociais da Doença , Dengue/economia , Absenteísmo , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Brasil/epidemiologia , Criança , Pré-Escolar , Dengue/epidemiologia , Feminino , Gastos em Saúde , Serviços de Saúde/estatística & dados numéricos , Humanos , Lactente , Entrevistas como Assunto , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Adulto Jovem
10.
World J Gastroenterol ; 21(4): 1197-206, 2015 Jan 28.
Artigo em Inglês | MEDLINE | ID: mdl-25632193

RESUMO

AIM: To evaluate the demographic characteristics and clinical phenotypes of inflammatory bowel disease (IBD) in a geographic area in Northeastern Brazil. METHODS: This retrospective study was conducted at the Hospital of the Federal University of Piauí in Northeastern Brazil. Demographic characteristics and clinical phenotypes of IBD were analyzed in relation to the time of diagnostic confirmation, which was defined as the date of disease onset. Data were collected between January 2011 and December 2012 and included all census patients 18 years of age or older during that period for whom there was diagnostic confirmation of Crohn's disease (CD), ulcerative colitis (UC), or unclassified colitis according to the Montreal criteria. We also analyzed the period of time between the onset of clinical manifestations and the diagnosis of IBD (delay in the diagnosis). Statistical analyses included means and standard deviations for numeric variables and the Pearson χ2 adherence test for nominal variables. The annual index occurrence and overall prevalence of IBD at our institution were also calculated, with P values<0.05 indicating statistical significance. This study was approved by the Institutional Ethics and Research Committee. RESULTS: A total of 252 patients with IBD were included, including 152 (60.3%) UC patients and 100 (39.7%) CD patients. The clinical and demographic characteristics of all patients with IBD showed a female to male ratio of 1.3:1.0 and a mean age of 35.2 (SD=14.5) years. In addition, the majority of patients were miscegenated (171, 67.9%), had received higher education (157, 62.4%), lived in urban areas (217, 86.1%), and were under the age of 40 years (97, 62.5%). For patients with CD, according to the Montreal classification, the predominant features present from the onset of disease were an age between 17 and 40 years (A2); colonic disease location (L2); and nonstricturing, nonfistulizing disease behavior (B1). However, approximately one-quarter of all CD patients demonstrated perineal involvement. We also observed considerable delay in the diagnosis of IBD throughout the entire study period (mean=35.5 mo). In addition, the annual index occurrence rose from 0.08 to 1.53 cases/10(5) inhabitants/year during the study period, and the prevalence rate was 12.8 cases/10(5) inhabitants in 2012. Over the last two decades, there was a noted increase in the frequency of IBD in the study area. CONCLUSION: In this study, there was a predominance of patients with UC, young people under 40 years of age, individuals with racial miscegenation, and low annual incomes.


Assuntos
Colite Ulcerativa/epidemiologia , Doença de Crohn/epidemiologia , Adulto , Distribuição por Idade , Fatores Etários , Idoso , Brasil/epidemiologia , Distribuição de Qui-Quadrado , Colite Ulcerativa/diagnóstico , Colite Ulcerativa/etnologia , Doença de Crohn/diagnóstico , Doença de Crohn/etnologia , Diagnóstico Tardio , Escolaridade , Feminino , Hospitais Universitários , Humanos , Renda , Masculino , Pessoa de Meia-Idade , Fenótipo , Pobreza , Valor Preditivo dos Testes , Prevalência , Características de Residência , Estudos Retrospectivos , Fatores de Tempo , Adulto Jovem
11.
J. bras. med ; 101(1): 41-47, jan.-fev. 2013. tab
Artigo em Português | LILACS | ID: lil-688978

RESUMO

O adequado controle terapêutico da diarreia aguda deve promover pronta e eficaz reidratação, oferecer suporte nutricional adequado, reduzir o número de evacuações e abreviar o tempo da doença. Esta revisão tem como objetivo apresentar os resultados de estudos recentes abordando a eficácia terapêutica de probióticos e prebióticos para as causas infecciosas de diarreia aguda.


Adequate therapeutic control of acute diarrhea should promote fast and effective rehydration, offer adequate nutritional support, reduce the number of bowel movements and shorten disease duration. The objective of this review is to present the results of recent studies regarding the therapeutic efficacy of probiotics and prebiotics for the treatment of infectious, acute diarrhea.


Assuntos
Humanos , Masculino , Feminino , Criança , Adulto , Diarreia/terapia , Prebióticos , Probióticos/uso terapêutico , Doença Aguda , Hidratação , Infecções/complicações , Apoio Nutricional , Ensaios Clínicos Controlados Aleatórios como Assunto , Saccharomyces/fisiologia , Simbióticos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...